

the **ADBL** report

Issue #90, March 1, 2016

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

EXPERT COMMITTEE MEMBERS:

Scott Klarenbach, MD, MSc (Health Econ), FRCPC
Saibal Nandy, MBBS, MRCPsych, FRCPC
Glen J. Pearson, BScPhm, PharmD, FCSHP
Cheryl A. Sadowski, BSc (Pharm), PharmD, FCSHP

ALBERTA HEALTH LIAISONS:

Michele Evans, BSP, MHSc (Health Admin)
Andrea Nagle, BSc (Pharm), LLB

ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Amanda Chung, BSc (Pharm)
Sherry Dieleman, BSc (Pharm), MSc
Connie Lussier, BSP, MA
Carlyn Volume-Smith, BSc (Pharm), MSc, PhD
Darcia Wasarab-Rolland, BSc (Pharm)

In this issue:

- **Brief Summary of Drug Review Activities**
- **Highlights of:**
 - ❖ **Products originally reviewed by CDR**
 - ❖ **Devices Added**
 - ❖ **Line Extension Drug Products**
 - ❖ **Other Drug Products Reviewed but Not Added**
 - ❖ **Interchangeable Drug Products Reviewed**
 - ❖ **Natural Health Products Reviewed**
- **Change in Listing Status**

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on January 21, 2016. The Committee reviewed Manufacturer submissions for thirty (30) Drug Products for potential listing, or change in listing, on the ADBL. The Committee also considered information for a number of supplementary assessments of the coverage status of twenty-six (26) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, thirty-nine (39) Drug Products underwent Expedited Review for listing on the ADBL effective March 1, 2016.

The following are highlights of recent changes to the ADBL and other topics of general interest. A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>

Highlights of Products Originally Reviewed by CDR

The following Drug Products were reviewed by CDR and the Expert Committee and added to the ADBL via Special Authorization effective March 1, 2016:

- **ACTEMRA*** (tocilizumab) (HLR) **162 mg/0.9 mL injection syringe** for the indication of Rheumatoid Arthritis
- **CIMZIA*** (certolizumab pegol) (UCB) **200 mg/mL injection syringe** for the indications of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
- **DIFICID*** (fidaxomicin) (MFC) **200 mg film-coated tablet**

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).

Highlights of Devices Added

The following Devices were added as Restricted Benefits to the *ADBL* effective March 1, 2016 after a Full review by the Expert Committee:

- **INSPIRACHAMBER*** (anti-static valved holding chamber) (LPC) **with mouthpiece, small mask/soothermask & medium mask/soothermask**

Highlights of Line Extension Drug Products Reviewed for the ADBL

The following Drug Product was added as a regular benefit to the *ADBL* effective March 1, 2016:

- **MYLAN-VALACYCLOVIR** (valacyclovir) (MYP) **1000 mg caplet**

Highlights of Other Drug Products Reviewed but Not Added

The following Drug Products were reviewed by the Expert Committee and have not been added to the *ADBL*:

- **JANUMET XR** (sitagliptin phosphate monohydrate/metformin hydrochloride) (MFC) **50 mg/500 mg, 50 mg/1000 mg & 100 mg/1000 mg extended-release tablets**
- **FORXIGA** (dapagliflozin propanediol monohydrate) (AZC) **5 mg & 10 mg tablets**

The following Drug Product was reviewed by the Expert Committee and has not been added to the *ADBL* because it does not offer a cost or therapeutic advantage:

- **ROSIVER** (ivermectin) (GAL) **1% topical cream**

In keeping with recommendations from the CDR, the following Drug Product has not been added to the *ADBL*:

- **ELELYSO** (taliglucerase alfa) (PFI) **200 unit/vial injection**

Highlights of Interchangeable Drug Products Reviewed

The following Drug Product was reviewed by the Expert Committee and added to the *ADBL* effective March 1, 2016:

- **AURO-VALACYCLOVIR** (valacyclovir) (AUR) **500 mg tablet**

The following Drug Product was reviewed by the Expert Committee and added to the *ADBL* via Optional Special Authorization effective March 1, 2016:

- **TEVA-MOXIFLOXACIN*** (moxifloxacin hydrochloride) (TEV) **400 mg tablet**

The following Drug Product was reviewed by the Expert Committee and added to the *ADBL* via Special Authorization effective March 1, 2016. This Drug Product will be interchangeable with Clindoxyl topical gel:

- **TARO-CLINDAMYCIN/BENZOYL PEROXIDE*** (clindamycin phosphate/ benzoyl peroxide) (TAR) **1%/5% topical gel**

Highlights of Natural Health Products Added

The following Natural Health Product has been added to the *ADBL* effective March 1, 2016:

- **JAMP-HYDROCORTISONE** (hydrocortisone) (JPC) **1% topical lotion**

Change in Listing Status

Current pricing and listing status was reviewed and the Expert Committee recommended that the benefit listing status of the following Drug Products be changed from Special Authorization to Regular benefits:

- **DUTASTERIDE** 0.5 mg capsules (all brands)
- **FINASTERIDE** 5 mg tablets (all brands)

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).*